MEDICINA DE PRECISÃO
Uma realidade no Centro-Oeste de Minas Gerais
DOI:
https://doi.org/10.61229/mpj.v1i2.20Keywords:
Hereditary Cancer Syndromes, Genetic Testing, Precision MedicineAbstract
The number of cancer cases in Brazil is on the rise, particularly in the South and Southeast regions. Among these cases, 5 to 15% have a hereditary component, increasing the risk of disease development. Given this scenario, it is crucial to define prevention, diagnosis, and monitoring strategies for these patients and their families. With this objective in mind, the "Hereditary Cancer Predisposition Assessment and Family Follow-up Program" was established in 2010 with the support of the Oncology Unit of Hospital São João de Deus, the Molecular Biology Laboratory of UFSJ, and the Associação de Combate ao Câncer do Centro-Oeste de Minas, all located in Divinópolis, Minas Gerais. The project was based on the development of a patient care flowchart to define monitoring strategies, utilizing a highly specialized team that includes genetic counseling, psychological support, and advanced techniques for molecular diagnosis. Since the inception of the project, approximately 350 families have met clinical criteria for hereditary syndromes, with Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and/or Li-Fraumeni Syndrome (n=250) being predominant. Among these families, 45% underwent genetic testing in the private sector, while 47% participated in the research project at UFSJ. Pathogenic mutations were identified in 28% of the tests. The identified pathogenic variants enable a more personalized approach to patient and family care, better-directing prevention, early diagnosis, and treatment strategies.
Downloads
References
Instituto Nacional do Câncer [Internet]. INCA [cited 2023 Sep 12]. Available from: https://www.gov.br/inca/pt-br.
Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2021 Nov;28(6):1167-1180. doi: 10.1007/s12282-020-01148-2. DOI: https://doi.org/10.1007/s12282-020-01148-2
NCCN Clinical Practice Guidelines in Oncology [Internet]. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic - Version 1.2024 [cited 2023 Aug 28]. Available from: https://www.nccn.org/guidelines/category_2.
Cipriano NM Jr., de Brito AM, de Oliveira ES, de Faria FC, Lemos S, Rodrigues AN, et al. Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil. Breast Cancer. 2019 May;26(3):397-405. doi: 10.1007/s12282-018-00938-z. DOI: https://doi.org/10.1007/s12282-018-00938-z
Oliveira ES, Soares BL, Lemos S, Rosa RC, Rodrigues AN, Barbosa LA, et al. Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis. Fam Cancer. 2016 Apr;15(2):173-81. doi: 10.1007/s10689-015-9858-0. DOI: https://doi.org/10.1007/s10689-015-9858-0
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mário Penna Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
- Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
- Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
- Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).
A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional